Related Experiment Video
Updated: Aug 8, 2026
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 2, 2013
Immunostimulatory CpG oligonucleotides reduce tumor burden after intravesical administration in an orthotopic murine
1Department of Urology and Pediatric Urology, Philipps University Marburg, Marburg, Germany. lexaelegeh@aol.com
Abstract:
Bacillus Calmette-Guérin is established in the prophylaxis of recurrent intermediate and high-risk superficial bladder cancer and induces an unspecific, Th1-biased local immune response. Small CpG oligonucleotides (CpG ODN) containing a central unmethylated CpG motif are able to mimic the immunostimulatory activity of bacterial DNA. The purpose of the present study was to evaluate the antineoplastic properties of intravesically administered CpG ODN in an orthotopic murine bladder cancer model. MB49 tumor cell suspension was instilled transurethrally in female C57/BL6 mice on day 0. Mice were divided in three groups of 12 animals. Four mice in each group received either stimulative CpG ODN, non-stimulative GpC ODN or PBS intravesically: group I on day 3, group II on day 5, group III on day 7. After sacrifice 7 days after treatment, bladders were removed and histological examinations were performed. Single instillation of CpG ODN revealed antineoplastic effects in every group demonstrated by significantly lower bladder weight compared with non-stimulative GpC ODN- and PBS-treated mice. Histological examination showed extensive infiltration of macrophages and lymphocytes in CpG ODN-treated mice, whereas PBS- and GpC ODN-treated mice showed solid tumor growth with only few leucocytes. Intravesically applied immunostimulative DNA demonstrated antitumoral activity in an orthotopic murine bladder cancer model. A single instillation seems to be sufficient to reduce tumor load.
Insights
Intravesically administered CpG oligonucleotides (CpG ODN) demonstrated significant antineoplastic effects in a murine bladder cancer model. A single dose of CpG ODN reduced tumor load and increased immune cell infiltration, suggesting therapeutic potential.
Area of Science:
- Immunology
- Oncology
- Urology
Background:
- Bacillus Calmette-Guérin is a standard treatment for superficial bladder cancer, inducing a Th1-biased immune response.
- CpG oligonucleotides (CpG ODN) mimic bacterial DNA to stimulate immune activity.
- Evaluating novel immunotherapies is crucial for improving bladder cancer treatment outcomes.
Purpose of the Study:
- To assess the antineoplastic properties of intravesically administered CpG ODN.
- To investigate the efficacy of CpG ODN in an orthotopic murine bladder cancer model.
- To determine the impact of CpG ODN on tumor growth and immune infiltration.
Main Methods:
- An orthotopic murine bladder cancer model was established using MB49 tumor cells in C57/BL6 mice.
- Mice received intravesical instillations of either stimulative CpG ODN, non-stimulative GpC ODN, or PBS.
- Bladder weight and histological examinations were performed 7 days post-treatment.
Main Results:
- CpG ODN treatment resulted in significantly lower bladder weights compared to control groups.
- Histological analysis revealed extensive macrophage and lymphocyte infiltration in CpG ODN-treated bladders.
- PBS and GpC ODN groups showed solid tumor growth with minimal immune cell presence.
Conclusions:
- Intravesically administered immunostimulative DNA (CpG ODN) exhibits significant antitumoral activity.
- A single instillation of CpG ODN appears sufficient to reduce tumor burden in this model.
- CpG ODN holds promise as a potential immunotherapy for superficial bladder cancer.
